News and Announcements
Crowd Mobile enters licensing agreement with AdsMetric
- Published August 05, 2015 4:31PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
5th August 2015, ASX Announcement
- Crowd Mobile enters exclusive agreement with Australian-based content developer AdsMetric Group to license and distribute premium social messaging platform “Krafty”
- License deal demonstrates Crowd Mobile’s strategy of broadening its content offering and leveraging its global m-Payment platform
- Agreement is expected to generate an additional source of revenue for Crowd Mobile
Crowd Mobile (ASX:CM8, FWB-XETRA : CM3) is please to announce that it has entered into an exclusive agreement with AdsMetric Group Pty Ltd (AMG), and Australian based content developer. The agreement allows Crowd Mobile to license and distribute AMG’s new premium social messaging platform “Krafty” through the Crowd Mobile platform, leveraging its global m-Payments capabilities.
Commenting on the agreement, Crowd Mobile Chief Executive Officer Domenic Carosa said:
“We are very excited about the AMG licensing agreement and being able to distribute new content to our customers. By leveraging our existing customer network and global m-Payments capabilities, we are adding an additional revenue source for the business.
Krafty has the power to seamlesly convey trending social media conversations and topics with a single moving image via SMS which can be forwarded to other friends, subsequently creating a ‘viral loop’ to rapidly increase the product’s user base”
To read the full announcement, please click here.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
